Showing 37,241 - 37,260 results of 226,405 for search '(( a ((((teer decrease) OR (a decrease))) OR (linear decrease)) ) OR ( a large decrease ))', query time: 1.58s Refine Results
  1. 37241
  2. 37242
  3. 37243
  4. 37244
  5. 37245
  6. 37246
  7. 37247
  8. 37248
  9. 37249
  10. 37250
  11. 37251
  12. 37252
  13. 37253
  14. 37254
  15. 37255

    In Vitro Screening for ToxCast Chemicals Binding to Thyroxine-Binding Globulin by Stephanie A. Eytcheson (4284421)

    Published 2024
    “…EPA’s ToxCast phase1_v2, phase 2, and e1k libraries for competitive binding to one of the carrier proteins, thyroxine-binding globulin. Initial screening at a single high concentration of 100 μM identified 714 chemicals that decreased signal of the bound fluorescent ligand by 20% or higher. …”
  16. 37256
  17. 37257

    Data_Sheet_5_Small Cetacean in a Human High-Use Area: Trends in Harbor Porpoise Abundance in the North Sea Over Two Decades.docx by Dominik A. Nachtsheim (9948494)

    Published 2021
    “…The overall trend for the German North Sea revealed a decrease in harbor porpoise abundance over the whole study period (−1.79% per year) with high probability (95.1%). …”
  18. 37258

    Data_Sheet_2_Small Cetacean in a Human High-Use Area: Trends in Harbor Porpoise Abundance in the North Sea Over Two Decades.docx by Dominik A. Nachtsheim (9948494)

    Published 2021
    “…The overall trend for the German North Sea revealed a decrease in harbor porpoise abundance over the whole study period (−1.79% per year) with high probability (95.1%). …”
  19. 37259

    Data_Sheet_4_Small Cetacean in a Human High-Use Area: Trends in Harbor Porpoise Abundance in the North Sea Over Two Decades.docx by Dominik A. Nachtsheim (9948494)

    Published 2021
    “…The overall trend for the German North Sea revealed a decrease in harbor porpoise abundance over the whole study period (−1.79% per year) with high probability (95.1%). …”
  20. 37260

    DataSheet_1_A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects.docx by Hong Zhang (25820)

    Published 2020
    “…Objective<p>This study was conducted to explore the tolerance, variability, pharmacokinetics (PK), and pharmacodynamics (PD) of denosumab biosimilar (QL1206) in healthy Chinese subjects.</p>Methods<p>This is a randomized, double-blind, two-arm, parallel study performed to examine the bioequivalence of denosumab biosimilar, QL1206, with that of Xgeva<sup>®</sup> (Denosumab) as a reference drug. …”